A clinician looking at data from Digital biomarkers and sensors

Clinical research

Providing accurate real-world evidence for successful clinical trials

Publications based on Syde technology

Filter by interest:

Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies

2023, European Medicines Agency (EMA)

First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD

2023, Nature Medicine

Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint

2024, Scientific Reports

Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device

2019, European Medicines Agency (EMA)

European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials

2019, Neuromuscular Disorders

Evolving regulatory perspectives on digital health technologies for medicinal product development

2023, NPJ Digital Medicine

EMA OKs First Digital Outcome As Primary Endpoint In Duchenne Studies

2023, Pink Sheet

The Importance and use of Syde® wearable Technology and the Stride Velocity 95th Centile (SV95C) Endpoint in Duchenne muscular dystrophy

2023, PPMD Italy Conference

Longitudinal multicentric study to validate SV95C in ambulant DMD aged 2-15 years old

2024, MDA Clinical & Scientific Conference

Longitudinal multicentric study to validate SV95C in ambulant DMD aged 2-15 years old

2024, International Congress of Myology

First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases

2021, Digital Biomarkers

Digital outcome captures longitudinal degradation of upper-limb function in non-ambulant patients affected by neuromuscular disorders

2023, Annual Congress of the World Muscle Society

Analysis of the natural evolution of SV95C in ambulant patients with Duchenne Muscular Dystrophy

2023, Annual Congress of the World Muscle Society

Factors affecting the measurement variability of SV95C in ambulant patients with Duchenne Muscular Dystrophy

2023, Annual Congress of the World Muscle Society

Longitudinal evaluation of ambulatory function with ankle wearable technology in ambulant DMD

2024, Annual Congress of the World Muscle Society

Wearable technology allows faster and more accurate detection of functional changes in Duchenne muscular dystrophy than traditional hospital-based tests

2021, Annual Congress of the World Muscle Society

Detecting positive and negative change in ambulant DMD boys using 95 centile stride velocity

2020, Annual Congress of the World Muscle Society

Analytical and clinical validation of a wearable-derived real-world stair climbing outcome in duchenne muscular dystrophy

2023, MDA Clinical & Scientific Conference

Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment

2021, Orphanet Journal of Rare Diseases

Longitudinal results of magneto-inertial motion analysis in DMD ambulant patients

2016, Neuromuscular Disorders

A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with DMD

2016, Plos One

Longitudinal home-monitoring data in non-ambulant patients with Duchenne muscular atrophy

2017, Neuromuscular Disorders

Feasibility and baseline values of continuous movement measurement in patients with centronuclear myopathy by using ActiMyo

2019, Neuromuscular Disorders

Innovative home activity monitoring in non-ambulant patients with SMA

2019, Neuromuscular Disorders

Wearable technology allows real world evidence of performances of patients with spinal muscular atrophy

2022, SMA Europe

ActiMyo home monitoring in adult patients with limb girdle muscular dystrophy type 2B and facioscapulohumeral muscular dystrophy in study ATYR 1940-C-004

2017, Annual Congress of the World Muscle Society

Assessment of lower limbs in FSHD: The ActiMyo as a new outcome for home-monitoring

2016, Annual Congress of the World Muscle Society

New criteria for assessing the achievement of upper limbs in FSHD patients

2016, Annual Congress of the World Muscle Society

ActiMyo home monitoring in adult patients with limb girdle muscular dystrophy type 2B and facioscapulohumeral muscular dystrophy in study ATYR 1940-C-004

2017, Neuromuscular Disorders

Wearable inertial sensors for longitudinal follow-up of patients with amyotrophic lateral sclerosis

2022, World Muscle Society

Digital mobility outcome measure in patients with Amyotrophic Lateral Scelorisis (ALS)

2024 MDA Clinical & Scientific Conference

Digital mobility outcome measure in patients with Amyotrophic Lateral Sclerosis (ALS)

2024, American Academy of Neurology

Analytical validation of innovative magneto-inertial outcomes: a controlled environment study

2022, European Committee for Treatment and Research in Multiple Sclerosis

A new digital measure to meaningfully assess daily-life ambulatory function of people with Multiple Sclerosis

2024, European Committee for Treatment and Research in Multiple Sclerosis

1-year follow-up data showing the potential of digital outcomes for Multiple Sclerosis clinical research

2024, American Academy of Neurology

Gait Digital Outcomes Exploration from Continuous Real-World Recordings in Parkinson’s Disease

2024, International Congress of Parkinson’s Disease and Movement Disorders

Qualitative Insights into Key Angelman Syndrome Motor Related Concepts Reported by Caregivers—A Thematic Analysis of Semi-Structured Interviews

2023, Children

Feasibility of using a wearable digital health technology sensor to assess ambulation in DM1 and CMT

2025, MDA Clinical & Scientific Conference

Feasibility of using a wearable digital health technology sensor to assess ambulation in DM1 and CMT

2025, MDA Clinical & Scientific Conference

Digital Outcomes for Quantifying Ambulation in People Living with ALS Using Wearable Sensors

2025, European Network to Cure ALS (ENCALS)

Paving the way for real-world measurement of ambulation in Ataxia Telangiectasia: a proof of concept in a controlled environment using a wearable device

2025, AT Clinical Research Conference 2025

Why use digital endpoints in clinical trials?

New mobility endpoints to accelerate the development of patient-centric therapies

Drug development requires reliable & sensitive endpoints to assess how patients feel, function, and survive. Validated digital technologies can provide precise and robust clinical assessments of motor function through continuous real-life patient monitoring.

The first-ever qualification by regulators of a digital endpoint, stride velocity 95th centile (SV95C) as a primary endpoint for Duchenne Muscular Dystrophy opens new possibilities for clinical trials. It shows the full potential of digital endpoints when they are robust, meaningful for patients, sensitive to change, validated by regulators, and adopted by the industry for drug development.

In the future, digital endpoints will play a key role in tracking treatment effectiveness and providing evidence for medical recommendations, enabling faster development & more personalized healthcare for patients.

Syde worn at the ankle

Functional assessments have many limitations

Traditional functional assessment of mobility involves in-clinic tests such as the 6-minute walk test (6MWT), the time 25-foot walk test (25FWT), the 10-meter test, 4 stair climbing test, or Time up-and-go (TUG).

These assessments of motor function have limitations:

For patients

Traditional assessments do not accurately represent what patients can do because they don’t consider short-term fluctuations like fatigue, or motivation. They also add a logistical burden to patients.

For regulators

Traditional assessments sometimes fail to show enough proof of a treatment's effectiveness. Regulators are confronted with ambiguity in assessing the drug's effectiveness because of inadequate data.

For drug developers

Traditional assessments of motor function fail to measure treatment effectiveness accurately. There have been recent examples of drug development being discontinued and reimbursement issues due to the inability of traditional assessments to highlight treatment efficacy.

Currently, The potential of Digital Health Technologies (DHTs] in clinical trials remains untapped.  It is because commercial wearables lack the analytical validity to be useful in clinical settings.

New technology is needed to bridge this gap and bring true value to patients, clinicians & decision-makers. Regulatory-grade wearables have the analytical ability to deliver precise digital health measurements and improve the traditional ‘gold standards’ all while ensuring the utmost privacy of the patient.

The pharma industry requires better endpoints to understand patient function

Why use digital endpoints in clinical trials :

Patient-Friendly

Digital endpoints and technologies enable convenient, non-intrusive monitoring of patients in their daily lives. This leads to higher compliance and retention rates in clinical trials:
- 4.53/5 score on the usability satisfaction scale.
- 93% compliance rate during clinical trials

More reliable and sensitive assessments

Digital endpoints offer more reliable and sensitive assessments than traditional methods. Continuous passive monitoring reduces bias and accurately reflects the patient's real-world function, providing a detailed picture of health status and treatment response.

Enable Shorter Study Timelines with Smaller Sample Sizes

Digital endpoints can detect treatment effects more quickly and with fewer patients; For instance, to demonstrate the same evolution in a statistically significant way, a DMD study would have to include 112 patients over 1 year using the 6MWT as opposed to 23 patients over 6 months using SV95C.

Decreases the cost of clinical trials

Digital endpoints could significantly increase the expected net present value (eNPV) of clinical trials, especially in phase 3 trials, where the increase in eNPV ranged from $27 million to $48 million. Thus, the community needs endpoints that can help to conclude faster and with more confidence on treatment benefits.

The Syde platform includes two wearable sensors for precise movement capture, a back-end IT platform with algorithms for digital endpoint calculation, and services for clinical operations.

SV95C: the qualification of the first digital endpoint by regulators opens new possibilities.

In 2023, the European Medicines Agency (EMA) officially qualified SV95C (Stride Velocity 95th Centile) as a primary endpoint with the European Medicines Agency (EMA) for superiority studies in Duchenne Muscular Dystrophy (DMD) patients 4 years of age and above. SV95C represents the speed of the top 5% fastest strides in the real life of patients. It is measured at the ankle using the fit-for-purpose Syde® or ActiMyo® wearables.
Watch a video from the DiMe Society's project Moneyball showing the tangible benefits digital biomarkers bring to clinical studies.

Alternative to traditional clinical assessments

This validation offers a valuable alternative to the 6-Minute Walking Test for evaluating ambulant DMD patients.

Increases clinical trials' probability of success:

SV95C is more sensitive to change compared to traditional gold standards. It shows the effect of treatment with statistical differences.

Adoption to other indications:

This qualification and the promising results in other pathologies open up new horizons, paving the way for the widespread adoption of digital endpoints as key evaluation criteria in clinical trials.

Beyond clinical trials, post-approval applications to redefine healthcare

Personalised treatment

By personalizing the treatment for every patient, the clinical treatment paradigm is shifting from a trial-and-error approach to "the right drug, at the right time, for the right patient."

R&D investments

Sysnav Healthcare invests in R&D and technologies that produce, manage, and analyze real-world data.

Healthcare transformation

By offering individualized and cost-effective personalized medical solutions, we aim to transform healthcare.